Discover
ALT
Altimmune, Inc.
3.15
2 x 2.44
2 x 3.89
bid
ask
+
0.11
3.62%
2 @ 07:00 AM
3.23 +0.08 (2.54%)
| Ytd | -12.74% | |
| 1y | -25.53% |
3.00
day range
3.40
2.56
52 week range
6.44
| Open | 3.02 | Prev Close | 3.04 | Low | 3.00 | High | 3.40 | Mkt Cap | 612.59M |
| Vol | 7.96M | Avg Vol | 4.21M | EPS | -0.92 | P/E | N/A | Forward P/E | -5.14 |
| Beta | 0.07 | Short Ratio | 5.81 | Inst. Own | 56.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 01-20 | Earning | 08-11 | 50-d Avg | 2.89 | 200-d Avg | 3.86 | 1yr Est | 22.86 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.36 | -0.32 | 0.04 | 11.11% |
| 2024-08-08 | 2024-06 | -0.34 | -0.35 | -0.01 | -2.94% |
| 2024-05-09 | 2024-03 | -0.36 | -0.34 | 0.02 | 5.56% |
| 2024-03-27 | 2023-12 | -0.35 | -0.33 | 0.02 | 5.71% |
| 2023-11-07 | 2023-09 | -0.4 | -0.39 | 0.01 | 2.50% |
| 2023-08-10 | 2023-06 | -0.44 | -0.32 | 0.12 | 27.27% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-12 | UBS | Upgrade | Buy | |
| 2024-08-12 | B. Riley Securities | Upgrade | Buy | Buy |
| 2024-06-25 | B. Riley Securities | Upgrade | Buy | Buy |
| 2024-06-21 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2024-05-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-08-18 | DRUTZ DAVID J | Director | 0.00 | Sale |
| 2024-01-30 | EISENSTADT RICHARD I | Chief Financial Officer | 45.01K | Stock Award(Grant) |
| 2024-02-01 | GARG VIPIN K. | Chief Executive Officer | 292.03K | Conversion of Exercise of derivative security |
| 2024-07-30 | HARRIS MATTHEW SCOTT | Officer | 55.12K | Stock Award(Grant) |
| 2024-07-30 | JORDT RAYMOND M | Officer | 14.66K | Stock Award(Grant) |
| 2024-07-30 | ROBERTS M SCOT | Officer | 43.33K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Blackrock Inc. | 5.47M | 41.27M | 7.69% |
| 2024-09-29 | Vanguard Group Inc | 4.98M | 37.63M | 7.01% |
| 2024-09-29 | Ameriprise Financial, Inc. | 3.88M | 29.26M | 5.45% |
| 2024-09-29 | State Street Corporation | 3.41M | 25.77M | 4.80% |
| 2024-09-29 | Tang Capital Management, LLC | 2.75M | 20.76M | 3.87% |
| 2024-09-29 | Geode Capital Management, LLC | 1.67M | 12.59M | 2.35% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 2.58M | 19.51M | 3.63% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.83M | 13.82M | 2.57% |
| 2024-09-29 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.79M | 13.52M | 2.52% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.10M | 8.29M | 1.54% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 727.87K | 5.50M | 1.02% |
| 2024-07-30 | Fidelity Strategic Advisors Small-Mid Cap Fund | 406.08K | 3.07M | 0.57% |
Dividend
| Dividend | Date |
|---|---|
| 291 | 2017-02-07 |
| 291 | 2017-02-06 |
| 291.003 | 2017-01-20 |
Split
| Split | Date |
|---|---|
| 1 : 30 | 2018-09-14 |
| 10 : 1 | 2017-05-05 |